Joint Clinical Trials Office

You are here

Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT)

Clinical Trial Details

The purpose of this study is to see if a new study drug, called semaglutide, has an effect on reducing the risk of cardiovascular (CV) events (e.g. heart attack and stroke) in subjects with overweight or obesity and with prior cardiovascular disease. The term “cardiovascular disease” refers to several conditions that affect your heart and blood vessels. These conditions include myocardial infarction (also known as a “heart attack”), a stroke (also known as a “brain attack”) and peripheral arterial disease (also known as” poor circulation”). Overweight and obesity is when your body stores too much body fat compared to your height. People living with overweight or obesity are more likely to have cardiovascular events and experience other health conditions. 

Semaglutide is a medication that doctors can prescribe in the US and other countries for the treatment of type 2 diabetes. Semaglutide is similar to a hormone made in your body after eating a meal. The hormone is called glucagon-like peptide-1 (GLP-1). Semaglutide works like your body’s own hormone to regulate your blood sugar (glucose) level and your appetite. Researchers have tested semaglutide in more than 5000 people. A completed study showed that semaglutide reduced the risk of cardiovascular events (e.g. heart attack and stroke) in subjects with type 2 diabetes. 

In this study, we will check to see if semaglutide may reduce the risk of having cardiovascular events. The dose in this study is higher than the dose used to treat type 2 diabetes. This is to see if a higher dose can reduce cardiovascular events in subjects without diabetes but with overweight or obesity. 

Key Eligibility: 
  • Male or female, age 45 or older 
  • Body mass index (BMI) of 27 kg/m2 or higher 
  • No history of type 1 or type 2 diabetes (history of gestational diabetes is allowed) 
  • Established CV disease as evidenced by at least one of the following: 

- prior myocardial infarction 
- prior stroke (ischemic or haemorrhagic stroke) 
- symptomatic peripheral arterial disease (PAD) or peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease 

Study contact by location

Upper East Side - Manhattan

Contact(s)

Anthony Joseph Casper
(646) 962-2424
anc2088@med.cornell.edu

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

1808019517

ClinicalTrials.gov:

NCT03574597

Status

Open to Enrollment

Age Group

Adult

Sponsor